Table 2 Treatment characteristics
Mean, Median (Range) | |
|---|---|
Total Prescribed Dose (Gy) | 76.4, 75.4 (65–90) |
SBRT Prescription IDL (%) | 80.8, 80.0 (70–92) |
Number of Boost Fractions | 5, 5, (5–5) |
SBRT Dose per Fraction (Gy) | 5, 5 (4–6) |
Total Boost Dose | 25, 25 (20–30) |
Duration of SBRT Treatment | 9, 7 (5–11) |
Number of IMRT Fractions | 27.6, 28, (25–30) |
IMRT Dose per Fraction | 1.87, 1.8 (1.8-2.0) |
Total IMRT Dose | 51.42, 50.40 (45–60) |
Duration of IMRT treatment | 41.5, 42 (35–49) |
Duration between IMRT and SBRT | 25, 20 (7–97) |
Cumulative BED10 | 98.8, 97.0 (81.1-120) |
Coverage | 95.7, 96 (80–100) |
NCI | 1.53, 1.43 (1.23-2.10) |
Chemotherapy (concurrent, sequential) | (15, 1) (94%, 6%) |